Page 2 - Limflow System News Today

Most patients avoided amputation in single-group study

LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced

The second round of late-breaking clinical trial results were presented at VIVA22 on Nov. 1 in Las Vegas, NV.

LimFlow Appoints Jenny Gaffney as Vice President, Health Economics and Reimbursement - read this article along with other careers information, tips and advice on BioSpace

LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced

LimFlow announced today that it closed an oversubscribed Series D financing round worth proceeds of $40 million (€36 million).

Funds to Support Completion of Clinical Program Through Commercialization of Novel Device Designed to Prevent Amputations in Patients with Chronic Limb-Threatening Ischemia LimFlow SA, a pioneer

/PRNewswire/ -- LimFlow SA, the pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a...